Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. | The primary growth drivers in Bayer’s pharma sector—Nubeqa and ...

Bayer is re-entering key assets in the US market under new indications to reclaim lost profits from patent expirations for its flagship therapies, a move it notes cannot be relied upon to face future ...

Bayer AG’s revenue will not plummet even though the company is facing patent expiries for some blockbuster drugs, according to its pharma head. “The patent cliff is more of a dent than a cliff,” ...

Among the potential blockbusters that could save the day for Bayer when top-selling meds Eylea and Xarelto fall off the patent cliff, the German company is touting one simply as “the kidney medicine.” ...

BOSTON/LONDON (Reuters) - The European Union should put mechanisms in place to allow drugmakers to charge higher prices in wealthy European countries and lower prices in poorer nations to assure more ...

Global big pharma Bayer, with 160 years of history, is confronting the patent cliff for its key medicines head-on with a new pipeline of drug candidates in development. With the prostate cancer drug ...